Penumbra Inc PEN

Penumbra’s strongest supplied fact is the latest filed quarter: revenue of $374.8M, operating income of $38.2M, net income attributable to the parent of $32.6M and diluted EPS of $0.82 for the 10-Q period ending 2026-03-31. That gives PEN a filing-backed operating story rather than a bare ticker description.

Penumbra Inc is an issuer in healthcare technology, with the official product rail pointing to thrombectomy systems and related medical devices. The supplied issuer evidence names THUNDERBOLT receiving FDA clearance for computer assisted vacuum thrombectomy technology to stroke, and also carries a practical device warning: automated high-pressure contrast injection equipment should not be used with the Penumbra Reperfusion Catheter because it may damage the device. The product story is therefore both clinical and operational, not just promotional.

The 2026-05-06 10-Q supplies the financial spine. Revenue from contract with customer, excluding assessed tax, was $374.8M for the period ending 2026-03-31. Assets were $1.90B, liabilities were $424.6M and stockholders' equity attributable to the parent was $1.47B. Cash and cash equivalents were $241.3M, net cash provided by operating activities was $87.0M, payments to acquire property, plant and equipment were $13.7M, inventory net was $438.5M and diluted weighted average shares were 39.5M.

No TradingView or chart route is supplied in the evidence list, so this file cannot state chart levels, candle behaviour, support, resistance or moving averages. The market mechanism that can be described is the public-source rail: SEC EDGAR filings, the issuer site, the SEC submissions JSON, the SEC companyfacts JSON and named filing events during May 2026.

The product and sales thread is also specific. The 10-Q says revenue from global thrombectomy products increased $27.4M, or 12.1%, to $253.9M in the three months ended 2026-03-31, from $226.5M in the three months ended 2025-03-31. That links the reported quarter to a concrete product category rather than leaving the revenue number floating alone.

What changed in the supplied rail is a cluster of May filings: an 8-K on 2026-05-06 announcing first-quarter results, the 10-Q on 2026-05-06, an 8-K on 2026-05-07 covering merger-related named executive officer compensation voting, a 425 on 2026-05-07, a Form 4 on 2026-05-21 and an SD filing on 2026-05-29. What remains unproven here is the current share price, chart setup, guidance detail, analyst view or post-filing operating update, because none is supplied.